The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure recommends that SGLT2 inhibitors “can be beneficial in decreasing HF hospitalizations and cardiovascular mortality” in patients with HFpEF (LVEF ≥ 50%) (Class of Recommendation 2a) [11]. This evidence concerns the gene SLC5A2 and heart failure.